search
Back to results

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009

Primary Purpose

Seasonal Influenza

Status
Completed
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
Influenza Vaccine, Formulation 2008-2009
Sponsored by
Novartis Vaccines
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Seasonal Influenza focused on measuring Influenza vaccine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Subjects eligible for enrollment into this study are male and female adults who are:

    1. ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry
    2. able to comply with all study requirements
    3. in good health as determined by:
  • medical history
  • physical examination
  • clinical judgment of the investigator

Exclusion Criteria:

  • They have any serious chronic or acute disease (in the judgment of the investigator) including but not limited to:

    1. Cancer, except for localized skin cancer;
    2. Advanced congestive heart failure;
    3. Chronic obstructive pulmonary disease (COPD);
    4. Autoimmune disease (including rheumatoid arthritis);
    5. Acute or progressive hepatic disease;
    6. Acute or progressive renal disease;
    7. Severe neurological or psychiatric disorder;
    8. Severe asthma.
  • They have history of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin and neomycin sulphate);
  • They have a known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from:
  • receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study;
  • receipt of immunostimulants;
  • receipt of parenteral immunoglobulin preparation, blood products and/or plasma derivates within the past 3 months and for the full length of the study;
  • suspected or known HIV infection or HIV-related disease;
  • They have a known or suspected history of drug or alcohol abuse;
  • They have a bleeding diathesis or condition associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject;
  • Women who are pregnant, or women able to bear children but not willing to practice acceptable contraception for the duration of the trial (21 days);
  • Within the past 12 months, they have:
  • received more than one injection of influenza vaccine
  • Within the past 6 months, they have:
  • had laboratory confirmed influenza disease;
  • received influenza vaccine;
  • Within the past 4 weeks they have received:
  • another vaccine;
  • any investigational agent;
  • They have any acute or chronic infection requiring systemic antibiotic treatment or antiviral therapy within the last 7 days; 1 - They have experienced an acute exacerbation of a COPD within the past 14 days

Sites / Locations

  • Site 1
  • Site 2
  • Site 3

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

1

Arm Description

Outcomes

Primary Outcome Measures

Evaluation of antibody response to each influenza vaccine antigen, as measured by Single Radial Hemolysis (SRH) test on Day 0 and on Day 21

Secondary Outcome Measures

Evaluation of safety

Full Information

First Posted
September 8, 2008
Last Updated
November 30, 2016
Sponsor
Novartis Vaccines
search

1. Study Identification

Unique Protocol Identification Number
NCT00748813
Brief Title
Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009
Official Title
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Sub
Study Type
Interventional

2. Study Status

Record Verification Date
December 2011
Overall Recruitment Status
Completed
Study Start Date
June 2008 (undefined)
Primary Completion Date
July 2008 (Actual)
Study Completion Date
July 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Vaccines

4. Oversight

5. Study Description

Brief Summary
Annual trial for registration influenza vaccine with the strain composition for season 2008/2009

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Seasonal Influenza
Keywords
Influenza vaccine

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
133 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Other
Intervention Type
Biological
Intervention Name(s)
Influenza Vaccine, Formulation 2008-2009
Intervention Description
1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
Primary Outcome Measure Information:
Title
Evaluation of antibody response to each influenza vaccine antigen, as measured by Single Radial Hemolysis (SRH) test on Day 0 and on Day 21
Time Frame
21 days (-1/+5)
Secondary Outcome Measure Information:
Title
Evaluation of safety
Time Frame
21 days (-1/+5)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects eligible for enrollment into this study are male and female adults who are: ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry able to comply with all study requirements in good health as determined by: medical history physical examination clinical judgment of the investigator Exclusion Criteria: They have any serious chronic or acute disease (in the judgment of the investigator) including but not limited to: Cancer, except for localized skin cancer; Advanced congestive heart failure; Chronic obstructive pulmonary disease (COPD); Autoimmune disease (including rheumatoid arthritis); Acute or progressive hepatic disease; Acute or progressive renal disease; Severe neurological or psychiatric disorder; Severe asthma. They have history of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin and neomycin sulphate); They have a known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from: receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study; receipt of immunostimulants; receipt of parenteral immunoglobulin preparation, blood products and/or plasma derivates within the past 3 months and for the full length of the study; suspected or known HIV infection or HIV-related disease; They have a known or suspected history of drug or alcohol abuse; They have a bleeding diathesis or condition associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject; Women who are pregnant, or women able to bear children but not willing to practice acceptable contraception for the duration of the trial (21 days); Within the past 12 months, they have: received more than one injection of influenza vaccine Within the past 6 months, they have: had laboratory confirmed influenza disease; received influenza vaccine; Within the past 4 weeks they have received: another vaccine; any investigational agent; They have any acute or chronic infection requiring systemic antibiotic treatment or antiviral therapy within the last 7 days; 1 - They have experienced an acute exacerbation of a COPD within the past 14 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Vaccines
Organizational Affiliation
Novartis Vaccines
Official's Role
Study Chair
Facility Information:
Facility Name
Site 1
City
Chieti
ZIP/Postal Code
66100
Country
Italy
Facility Name
Site 2
City
Lanciano
ZIP/Postal Code
66034
Country
Italy
Facility Name
Site 3
City
Pianiga
ZIP/Postal Code
30034
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009

We'll reach out to this number within 24 hrs